'Residual disease' diaporamas de présentation

Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. ASH Review 2012 Stephen Spurgeon (spurgeos@ohsu.edu). Disclosures. Speakers Bureau: GSK, Millenium , Cephalon. CLL: Pertinent Topics. ASH treatment updates James DF, et al. ASH 2011. Abstract 291.

1.18k views • 84 slides

Novak 33. Ovarian ca

Novak 33. Ovarian ca. Nonepithelial Ovarian Cancers ????? ???? R2 ???. Nonepithelial Ovarian Cancers . Compared with epithelial ovarian cancers, other malignant tumors of the ovary are uncommon about 10% of all ovarian cancers 1. malinancies of germ cell origin,

1.51k views • 76 slides

GYNECOLOGICAL TUMORS

GYNECOLOGICAL TUMORS. RATH 4412. EPIDEMIOLOGY AND ETIOLOGY. Incidence rates- 2010 Endometrial (uterine corpus) 43,470 new cases Ovarian 21,880 new cases Cervical 12,200 new cases of invasive cancer Other 2,300 Death rates- 2010 Ovarian, ranks 5 th among cancer deaths for women- 13,850

808 views • 62 slides

Surveillance of patients after initial treatment of ovarian cancer Angiolo Gadducci

Mediterranean School of Oncology Highlights in the management of ovarian cancer . Surveillance of patients after initial treatment of ovarian cancer Angiolo Gadducci Department of Gynecology and Obstetrics, Unit of Gynecologic Oncology, University of Pisa Rome October 5-6 2007.

785 views • 58 slides

Testicular tumors

1.55k views • 55 slides

Serous Epithelial Ovarian Cancers: A Pathologic and Clinical Perspective

Serous Epithelial Ovarian Cancers: A Pathologic and Clinical Perspective. Amanda Nickles Fader, MD Associate Professor, The Kelly Gynecologic Oncology Service Johns Hopkins Medicine. Disclosures. I have no financial relationships to disclose. My First Patient: Erin. Optimal Debulk to R0

508 views • 50 slides

Investigations of lymphoma

Investigations of lymphoma. FBE / CBC U&E LFT ESR LDH Beta 2 microglobulin Protein electrophoresis HIV and HTLV II serology. General blood tests. Look for:anaemia , ? WCC, lymphopenia , neutrophilia / neutropenia , eosinophilia. FBE.

730 views • 41 slides

MRD is a powerful prognostic factor in AML.

Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML). Although most pts with AML (> 80%) achieve CR following induction therapy, relapse is common and a major cause of treatment failure

106 views • 10 slides

Grammel et al. Suppl. Figure 1

Grammel et al. Suppl. Figure 1. a. b. CN contact (n=21). CN contact (n=21). p=<0.0001. p=0.287. No CN contact (n=42). No CN contact (n=42). 100. 40. 80. 30. 60. Survival [%]. Case density [%]. 20. 40. 10. 20. 0. 0. 0. 4. 5. 1. 2. 3. 6. 7. 8. 0-3. 3-6. 6-9. 9-12.

93 views • 1 slides

Identify that you have NET disease as opposed to symptoms caused by another condition.

VIII. What questions can it answer?. Identify that you have NET disease as opposed to symptoms caused by another condition. If there is uncertainty as to whether a tumor is a NET, it will confirm this.

65 views • 1 slides